Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
C. R. Bard
The hypothesis to be statistically tested was that the RIVS system will have a higher rate of successful first attempt peripheral intravenous placement success as compared to conventional peripheral intravenous catheters without a significant increase in device related complications and procedure time.
Age
5–90
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Any type of oncology patients undergoing chemotherapy or post-chemotherapy (without a port/cannula), or over 65 years
Requires peripheral IV as determined by examining physician
Requires the IV when a study nurse or resident is available
Able to sign an informed consent
You may not be if
Active systemic or cutaneous infection or inflammation;
Pre-existing immunodeficiency disorder and/or chronic use of systemic steroids;
Known, significant history of bleeding diathesis, coagulopathy, von Willebrand's disease or current platelet count \< 100,000 cells/mm3, baseline International Normalized Ratio (INR) ≥1.8, or fibrinogen level less than 150 mg/dl (if received a fibrinolytic agent within prior 24 hours);
Currently involved in any other investigational clinical trials;
Previous vascular grafts or surgery at the target vessel access site;
Females who are pregnant, planning to become pregnant within 3 months of the procedure, or lactating;
Central line available
Requirement for immediate IV placement (patient's condition would potentially be compromised if there is a time delay in IV placement)
Clareo Health | Effectiveness of the Rapid Intravascular Start (RIVS) System Versus Conventional Catheter
